comparemela.com

Latest Breaking News On - Puretech health - Page 3 : comparemela.com

PRTC to Present at Jefferies Healthcare Conference | Company Announcement

Investegate announcements from PRTC to Present at Jefferies Healthcare Conference

United kingdomEric elenkoNichole bobbynRob winderBharatt chowriraBen atwellPuretech healthTech healthJefferies global healthcareChief executive officerJefferies global healthcare conferenceFounded entitiesPrivate securities litigation reform actAnnual report

PureTech to Present at the Jefferies Global Healthcare Conference

BOSTON (BUSINESS WIRE) May 23, 2024

United statesBen atwellNichole bobbynBharatt chowriraRob winderEric elenkoPuretech healthTech healthChief executive officerJefferies global healthcare conferenceBusiness wireFounded entitiesNote regarding forward looking statementsPrivate securities litigation reform actAnnual report

Carbon Biosciences Announces New Appointments to Board of Directors and Scientific Advisory Board

- Carol Ann Satler, MD, PhD, FACC, FAHA, FAAP joins the Board of Directors, adding key clinical experience to guide ongoing nonclinical development in cardiac.

Harvard universityUnited statesCase western reserve universityCarol annLloyd klicksteinJoel schneiderEli lillyCarol ann satlerPuretech healthAmerican college of rheumatologyNovartis institutes for biomedical researchCarbon teamCarbon biosciences incAmerican academy of pediatricsHarvard medical schoolAmerican college of cardiology

Ashurst Guides PureTech s Proposed $100M Tender Offer

Ashurst Guides PureTech s Proposed $100M Tender Offer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomElouise johnstonSharon kimMark spinneyNicholas gardnerSimon bullockJeffrey johnsonStuart rubinJefferies internationalPuretech healthJefferies international limitedAmerican depositary sharesCall optionNew york based

PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C difficile Infection

VE303 is an orally administered, potential first-in-class live biotherapeutic product candidate being developed to prevent recurrence of Clostridioides difficile infection .

United kingdomJeffrey silberPaul feuerstadtPuretech healthDevelopment authorityBiomedical advanced researchUs department of healthDrug administrationYale university school of medicineAdministration for strategic preparednessHuman servicesFounded entityVedanta biosciencesBiologics license applicationBiosciences enrolls first patientPivotal phase

vimarsana © 2020. All Rights Reserved.